Study on the binding mode of a pyrrolotriazin derivative with JAK2 by docking and MD simulation

References

• Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322. doi: 10.1146/annurev.immunol.16.1.293
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Saharinen P, Pesu M, et al. The janus kinases (jaks). Genome Biol. 2004;5:253–258. doi: 10.1186/gb-2004-5-12-253
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105. doi: 10.1038/nrc1275
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161–170. doi: 10.1056/NEJMra1202117
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective. Blood Rev. 2011;25:229–237. doi: 10.1016/j.blre.2011.06.002
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061. doi: 10.1016/S0140-6736(05)74230-6
   PubMed Web of Science ®Google Scholar
• Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opin Investig Drugs. 2013;22:775–785. doi: 10.1517/13543784.2013.775244
   PubMed Web of Science ®Google Scholar
• Kim MH, Son YJ, Lee SY, et al. JAK2-targeted anti-inflammatory effect of a resveratrol derivative 2,4-dihydroxy-N-(4-hydroxyphenyl) benzamide. Biochem Pharmacol. 2013;86:1747–1761. doi: 10.1016/j.bcp.2013.10.006
   PubMed Web of Science ®Google Scholar
• Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs. 2013;22:687–699. doi: 10.1517/13543784.2013.774373
   PubMed Web of Science ®Google Scholar
• Wan H, Schroeder GM, Hart AC, et al. Discovery of a Highly Selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms. Med Chem Lett. 2015;6:850–855. doi: 10.1021/acsmedchemlett.5b00226
   Google Scholar
• Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood. 2012;119:2721–2730. doi: 10.1182/blood-2011-11-395228
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Mesa RA. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opin Pharmaco. 2014;15:1265–1276. doi: 10.1517/14656566.2014.913024
   PubMed Web of Science ®Google Scholar
• Abdelrahman RA, Begna KH, Al-Kali A, et al. Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia. 2015;29:498–500. doi: 10.1038/leu.2014.286
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262–3270. doi: 10.1182/blood-2006-04-015560
   PubMed Web of Science ®Google Scholar
• Zificsak CA, Gingrich DE, Breslin HJ, et al. Optimization of a novel kinase inhibitor scaffold for the dual inhibition of jak2 and fak kinases. Bioorg Medl Chem Lett. 2012;22:133–137. doi: 10.1016/j.bmcl.2011.11.049
   PubMed Web of Science ®Google Scholar
• Chen YC. Beware of docking. Trends Pharmacol Sci. 2014;36:78–95. doi: 10.1016/j.tips.2014.12.001
   PubMed Web of Science ®Google Scholar
• Liao S-Y, Chen J-C, Mo G-Q, et al. A computational study of binding between 3-(4-fluorophenyl)–((4-fluorophenyl)sulphonyl)acrylamide and tubulin. Mol Simulat. 2015;41:356–364. doi: 10.1080/08927022.2014.894242
   Web of Science ®Google Scholar
• CambridgeSoft corp, 100 Cambrige Park, MA 02140e2317, USA.
   Google Scholar
• Discovery Studio 2.0, Accelrys Software Inc; 2007.
   Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785–2791. doi: 10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Chen J, Wang J, Zhu W. Zinc ion-induced conformational changes in new Delphi metallo-β-lactamase 1 probed by molecular dynamics simulations and umbrella sampling. Phys Chem Chem Phys. 2017;19:3067–3075. doi: 10.1039/C6CP08105C
   PubMed Web of Science ®Google Scholar
• Chen J, Wang J, Mutation ZW. Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling. Phys Chem Chem Phys. 2017;19:30239–30248. doi: 10.1039/C7CP05418A
   PubMed Web of Science ®Google Scholar
• Case DA, Cheatham TA, Simmerling CL, et al. AMBER 10. San Francisco (CA): University of California; 2008.
   Google Scholar
• Becke AD. A new mixing of Hartree–Fock and local density-functional theories. J Chem Phys. 1993;98:1372–1377. doi: 10.1063/1.464304
   Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09, revision A.1. Wallingford (CT): Gaussian, Inc; 2009.
   Google Scholar
• Bayly CI, Cieplak P, Cornell WD, et al. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem. 1993;97:10269–10280. doi: 10.1021/j100142a004
   Web of Science ®Google Scholar
• Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157–1174. doi: 10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926–935. doi: 10.1063/1.445869
   Web of Science ®Google Scholar
• Essman U, Perera L, Berkowitz ML, et al. A smooth particle mesh Ewald method. J Chem Phys. 1995;103:8577–8593. doi: 10.1063/1.470117
   Web of Science ®Google Scholar
• Andersen HC. Rattle: a “velocity” version of the shake algorithm for molecular dynamics calculations. J Comput Phys. 1983;52:24–34. doi: 10.1016/0021-9991(83)90014-1
   Web of Science ®Google Scholar
• Fogolari F, Brigo A, Molinari H. Protocol for MM/PBSA molecular dynamics simulations of proteins. Biophys J. 2003;85:159–166. doi: 10.1016/S0006-3495(03)74462-2
   PubMed Web of Science ®Google Scholar